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Aortic implantation of anomalous left 
coronary artery 
To the Editor: 
My attention was drawn, rather belatedly, to the excel- 
lent article by Laks and associates in the March 1995 issue 
of the Journal (1995;109:519-23). In this, they described 
an improved surgical approach to the implantation of the 
anomalous left coronary artery, which they have used 
since April 1990. My colleagues and 11 described this 
technique in a report in The Annals of Thoracic Surgely in 
1986, having used it in a baby who had been operated on 
in 1981. They failed to refer to it. 
As I often say to my own junior staff when writing an 
article, thoroughness of the literature review is one of the 
basic essentials and would avoid such an omission. 
Hugh O'Kane, FRCS 
Consultant Cardiac Surgeon 
Cardiac Surgical Unit 
The Royal Hospital 
Belfast, Northern Ireland 
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Use of epsilon-aminocaproic acid to reduce 
bleeding 
To the Editor." 
The recent publication by Vander Salm and associates 1 
concerning the use of epsilon-aminocaproic acid (EACA) 
to reduce bleeding after cardiac operations describes a 
carefully conducted, randomized, double-blind, placebo- 
controlled study investigating the efficacy of a high dose of 
EACA in patients requiring heart surgery. The results 
show EACA use to be associated with smaller mean 
volumes of postoperative chest ube drainage than did use 
of saline solution. This reduction was modest, however, 
inasmuch as it totaled less than 200 ml per patient over the 
24-hour period. The reduction in bleeding did not trans- 
late into a clinical benefit, for there was no difference 
between the EACA group and the placebo group in the 
transfusion of red blood cells, transfusion of other blood 
products, or in the mean hematocrit levels of the patients 
at discharge. 
Despite these essentially negative results, the authors 
have extrapolated from their data the conclusion that 
"EACA reduces postoperative bleeding after heart 
operations at far less expense than aprotinin." This is a 
curious deduction since EACA was not compared with 
aprotinin in their study; data regarding aprotinin effec- 
tiveness are not provided. To conclude that one drug is 
preferable to another in producing a certain effect, one 
must compare the two drugs; such a comparison is not 
provided in the study described by the authors. 
In their discussion and conclusions, Vander Sahn and 
associates address only the cost aspects of EACA and 
aprotinin while ignoring the relative benefits of the two 
drugs. Cost-benefit comparisons should compare both 
cost and benefit. EACA certainly costs less than apro- 
tinin, but is it of benefit? The results reported by Vander 
Salm's group fail to demonstrate any benefit with 
EACA use, as compared with saline solution, in clini- 
cally important parameters uch as reduced transfu- 
sions of blood products or higher postoperative hemat- 
ocrit levels. Despite this, without supportive data, the 
authors tate in their discussion that "aprotinin [is] at a 
considerable disadvantage in the choice between the 
two drugs on the basis of a cost-benefit analysis." On 
the basis of their results, however, it appears that 
EACA is at the disadvantage because no clinically 
important benefit was associated with its use in this 
study. No matter how low the cost, without a benefit 
there is no cost-benefit advantage. To be cost-effective 
a drug must first be effective. 
Several multicenter, andomized, double-blind North 
American studies involving more than 1375 patients 
have demonstrated clear-cut aprotinin efficacy in reduc- 
ing transfusions (not just bleeding) by approximately 
50% as compared with placebo) Because transfusions 
are reduced, the cost of aprotinin (about $450 for the 
"half-dose" regimen) is offset, in whole or in part, by 
the reduction in costs of the blood products themselves, 
and several studies have demonstrated aprotinin use to 
be cost-advantageous when the costs of both the blood 
products and the drug are analyzed. 3-5 Such consider- 
ations were not included in the discussion and conclu- 
sions provided by Vander Salm and associates. 
I have two further comments: 
Vander Salm and associates have referenced the paper 
by Laub and coworkers 6 as evidence that aprotinin causes 
graft closure. They do not point out, however, that the 
publication by Laub described the single-center results 
(Deborah Heart and Lung Center) of a small number of 
patients who participated in a large multicenter trial 
(University of Iowa, Mayo Clinic, University of Illinois at 
Chicago, University of Chicago, and Deborah Heart and 
Lung Center). The results of the multicenter investigation 
were published earlier 7 and, with 170 patients and 476 
grafts, did not confirm the results of the 32 patients and 81 
grafts described by Laub's group. In the multicenter t ial, 
which included the patients reported on later by the 
Laub's group, an adverse ffect on vein graft patency rates 
was not demonstrated although, as pointed out by the 
authors, the number of grafts did not provide sufficient 
statistical power for absolute conclusions in this regard. 
The reasons for a higher, although not statistically signif- 
icant, graft closure rate in the aprotinin-treated patients 
from the single center eported by Laub and associates are 
not clear. 
The "commonly used high-dose aprotinin regimen" 
described by Vander Salm and colleagues in their discus- 
sion is an unusual dose; references to its source are not 
provided. It does not correspond to the original high-dose 
(Hammersmith) regimen described by Royston and co- 
workers 8nor to the high-dose, half-dose, or pump-prime- 
only doses investigated invarious published trials. In fact, 
the dose described by Vander Salm's group is approxi- 
mately ten times higher than the dose suggested in the 
